We have established a platform technology that leverages various biotech techniques, from recombinant proteins to genetic materials, to rapidly respond to a wide range of infectious diseases. Using this platform, we are swiftly developing vaccines and therapeutics against pathogens and novel viruses that could be exploited for biological threats.